Literature DB >> 1699659

Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.

J L Grem1, C J Allegra.   

Abstract

We evaluated the interaction of a biochemically active concentration of cyclopentenyl cytosine (CPE-C), an investigational antimetabolite which inhibits CTP synthetase, on the cytotoxicity of arabinosyl-5-azacytosine (Ara-AC) and 1-beta-D-arabinofuranosylcytosine (Ara-C) in HCT 116 colon carcinoma cells. A 3-h exposure to 0.5 microM CPE-C depleted CTP pools by over 90% and decreased dCTP pools by 57%; the effect on CTP pools persisted for up to 24 h following washout of CPE-C. A 3-h pre-exposure to 0.5 microM CPE-C augmented the growth inhibition resulting from a 24-h exposure to Ara-AC. The combination of 1 microM cytidine and deoxycytidine fully reversed the enhancement associated with CPE-C pretreatment, to a level of growth inhibition expected from either CPE-C or Ara-AC alone. A striking enhancement of toxicity was observed in clonogenic studies with pre-exposure to CPE-C at a nonlethal dose followed by either Ara-AC or Ara-C. CPE-C increased the formation of Ara-AC and Ara-C nucleotides by as much as 3-fold, and this was accompanied by increased incorporation of the arabinosyl nucleotides into methanol-precipitable material. Analysis of purified RNase-treated nucleic acids by cesium sulfate density centrifugation confirmed that a 3-h pre-exposure to CPE-C increased [3H]-Ara-C incorporation into DNA at 4 and 24 h by 2.4- and 2.7-fold, respectively. Thus, these studies indicate that CPE-C can function as a biochemical modulator. Following a brief exposure to a nonlethal concentration, CPE-C is capable of augmenting the cytotoxicity and intracellular metabolism of Ara-AC and Ara-C.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1699659

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Authors:  J L Abbruzzese; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Phase I clinical trial of continuous infusion cyclopentenyl cytosine.

Authors:  P M Politi; F Xie; W Dahut; H Ford; J A Kelley; A Bastian; A Setser; C J Allegra; A P Chen; J M Hamilton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase.

Authors:  E De Clercq; J Murase; V E Marquez
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

4.  Determinants of trimetrexate lethality in human colon cancer cells.

Authors:  J L Grem; D M Voeller; F Geoffroy; E Horak; P G Johnston; C J Allegra
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.